Marketing analysis of the assortment of diclofenac sodium drugs in the pharmaceutical market of Ukraine.

Abstract

Rheumatic diseases are the most common cause of disability, which includes a heterogeneous group of connective tissue diseases (dermis, tendon-ligamentous apparatus, cartilage, bone tissue, synovial and serous membranes, basement membranes of vessels, etc.), which has a multifactorial and not fully understood etiology. Conservative treatment mainly includes non- steroidal anti-inflammatory drugs (NSAIDs) remain the most effective and frequently used means for the treatment of this pathology. Diclofenac sodium, a phenylacetic acid derivative, is a nonsteroidal anti-inflammatory, analgesic agent recommended for use in rheumatoid arthritis, degenerative joint disease, ankylosing spondylitis, and related conditions, as well as for the treatment of pain resulting from minor surgery, trauma, etc. On the pharmaceutical market, it is presented in various dosage forms, which allows you to use the drug both in chronic conditions and in case of exacerbation of the disease. The mechanism of action of the drug is based on the non- selective inhibition of cyclooxygenase (COX-1,2), and the physiological effect of this substance is due to a decrease in the production of prostaglandins, revealing a typical triad of pharmacological effects - analgesic, anti-inflammatory and antipyretic. Since diclofenac penetrates the synovial fluid, where its maximum concentration is reached 2-4 hours later than in the blood plasma, that is why the drug is the drug of choice for inflammatory and degenerative forms of rheumatic diseases. The aim of the study is to conduct a marketing analysis of the range of diclofenac sodium drugs registered in the pharmaceutical market of Ukraine and to determine the prospects for their further use in medicine.